Clinical Trials
180
39 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1909
Active, not recruiting
35
19.4%
Completed
75
41.7%
Not yet recruiting
4
2.2%
Recruiting
45
25.0%
Terminated
14
7.8%
Unknown
7
3.9%
No approval data available
- The ASTER 70 phase III trial involving 1,089 patients aged 70 and older with high-risk ER+HER2- breast cancer found no significant overall survival benefit from adding chemotherapy to hormone therapy. - After 7.8 years of follow-up, four-year survival rates were 90.5% with chemotherapy versus 89.3% with hormone therapy alone, while eight-year rates were 72.7% versus 68.3% respectively. - Patients receiving chemotherapy experienced significantly more grade 3 or higher adverse events (34% versus 9%) and reported worse quality of life including increased fatigue, pain, and digestive disorders. - The findings challenge current treatment standards and support more individualized approaches for elderly breast cancer patients based on age, frailty, and patient preferences rather than tumor biology alone.
- The PEVOsq phase 2 trial demonstrated a 26% overall response rate with pembrolizumab plus vorinostat in 107 patients with recurrent/metastatic squamous cell carcinoma across multiple anatomical sites. - Primary endpoints were met in cervical cancer (39% ORR), anal cancer (31% ORR), and vulvar/vaginal cancer (19% ORR) cohorts, with median overall survival reaching 18.8 months in anal cancer patients. - Treatment-related adverse events occurred in 91% of patients, with 75% requiring dose modifications, though the safety profile was deemed manageable despite substantial toxicity. - Biomarker analysis identified PD-L1 positivity, HPV status, and high tumor mutational burden as predictive factors for response to the combination therapy.
- Egle Therapeutics has received €9.3 million in non-dilutive funding from France 2030's "Innovations in Biotherapies and Bioproduction" initiative to accelerate development of its lead immuno-oncology candidate EGL-001. - The clinical-stage biotech, a 2020 spin-off from Institut Curie, has developed a proprietary platform to identify novel tumor-infiltrating regulatory T cell (Treg) targets for cancer and autoimmune disease treatments. - Since its founding, Egle has raised nearly €56 million through equity financing and non-dilutive funding, with its lead candidate EGL-001 currently in Phase I/II clinical trials in France and Spain.
• TKIs target the intracellular kinase domain of HER2, inhibiting cell proliferation pathways, while ADCs utilize antibodies to deliver cytotoxic payloads directly to cancer cells. • HER2-directed ADCs demonstrate broader efficacy across various HER2 alterations, including mutations, amplifications, and overexpression, offering versatile treatment options. • TKIs offer advantages of oral administration and established safety profiles, though their effectiveness can vary depending on specific HER2 mutations in the ATP binding domain.
- Valerio Therapeutics has acquired Emglev Therapeutics, gaining access to innovative single-domain antibody (sdAb) technology that enables fully human antibody development through in vitro processes. - The acquisition, executed through Valerio's subsidiary Valour Bio, strengthens their therapeutic pipeline with applications in autoimmune diseases, inflammatory disorders, and cancer treatment modalities. - Emglev's platform has demonstrated preclinical success with various therapeutic approaches, including CAR-T sdAb, BiTE sdAb, and sdAb-drug conjugates, promising accelerated development with reduced immunogenicity risks.
- The VESPER trial's molecular subtyping analysis reveals the BaSq subtype (pure or mixed) is associated with decreased progression-free survival and overall survival in bladder cancer patients. - Patients in the neoadjuvant setting who received dose-dense MVAC chemotherapy showed significantly higher three-year progression-free survival compared to those receiving gemcitabine and cisplatin. - Extended follow-up of the VESPER trial demonstrated improved overall survival at 5 years in the dose-dense MVAC group versus the gemcitabine + cisplatin group within the neoadjuvant subgroup. - Further research is needed to understand the biological bases for mixed tumors and to improve prognosis for BaSq subtype tumors.
• The LUMINOSITY trial showed telisotuzumab vedotin (Teliso-V) yielded a 29% response rate in patients with c-Met-overexpressing, EGFR wild-type, nonsquamous NSCLC. • Patient-reported outcomes from LUMINOSITY indicated improvements in key cancer-related symptoms like cough and chest pain with Teliso-V treatment. • The trial also demonstrated that Teliso-V maintained quality of life and physical functioning, particularly in patients achieving disease control. • Peripheral neuropathy, a notable side effect, was reported by patients, highlighting the need for proactive management in subsequent trials.
